CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Vincerx Pharma, Inc. - VINC CFD

5.15
20.05%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.08
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Vincerx Pharma Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 4.29
Open* 4.26
1-Year Change* 257.98%
Day's Range* 4.23 - 5.23
52 wk Range 0.61-1.95
Average Volume (10 days) 2.69M
Average Volume (3 months) 10.31M
Market Cap 24.59M
P/E Ratio -100.00K
Shares Outstanding 21.38M
Revenue N/A
EPS -2.30
Dividend (Yield %) N/A
Beta 0.10
Next Earnings Date Mar 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 4, 2024 5.15 0.82 18.94% 4.33 5.53 4.19
Mar 1, 2024 4.29 0.66 18.18% 3.63 4.40 3.63
Feb 29, 2024 3.73 -0.05 -1.32% 3.78 3.83 3.56
Feb 28, 2024 3.76 -0.12 -3.09% 3.88 4.24 3.69
Feb 27, 2024 3.98 0.24 6.42% 3.74 4.05 3.56
Feb 26, 2024 3.81 0.28 7.93% 3.53 4.01 3.33
Feb 23, 2024 3.51 -0.25 -6.65% 3.76 3.76 3.15
Feb 22, 2024 3.78 0.70 22.73% 3.08 4.10 3.08
Feb 21, 2024 2.99 0.02 0.67% 2.97 3.33 2.71
Feb 20, 2024 3.05 1.28 72.32% 1.77 3.64 1.68
Feb 16, 2024 1.78 0.12 7.23% 1.66 1.78 1.62
Feb 15, 2024 1.70 0.00 0.00% 1.70 1.76 1.64
Feb 14, 2024 1.73 0.01 0.58% 1.72 1.75 1.63
Feb 13, 2024 1.71 0.13 8.23% 1.58 1.74 1.53
Feb 12, 2024 1.68 0.14 9.09% 1.54 1.80 1.50
Feb 9, 2024 1.49 0.14 10.37% 1.35 1.56 1.33
Feb 8, 2024 1.32 -0.05 -3.65% 1.37 1.42 1.25
Feb 7, 2024 1.36 0.01 0.74% 1.35 1.41 1.29
Feb 6, 2024 1.34 0.16 13.56% 1.18 1.38 1.17
Feb 5, 2024 1.17 0.00 0.00% 1.17 1.19 1.13

Vincerx Pharma, Inc. Events

Time (UTC) Country Event
Tuesday, March 26, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Vincerx Pharma Inc Earnings Release
Q4 2023 Vincerx Pharma Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 9, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Vincerx Pharma Inc Earnings Release
Q1 2024 Vincerx Pharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2020 2019
Total revenue 0 0 0 0 0
Total Operating Expense 73.574 62.656 10.714 0.173 0.00145
Other Operating Expenses, Total 0.173 0.00145
Operating Income -73.574 -62.656 -10.714 -0.173 -0.00145
Net Income Before Taxes -65.367 -39.306 -16.62 -0.11873 -0.00145
Net Income After Taxes -65.367 -39.306 -16.62 -0.11954 -0.00145
Net Income Before Extra. Items -65.367 -39.306 -16.62 -0.11954 -0.00145
Net Income -65.367 -39.306 -16.62 -0.11954 -0.00145
Income Available to Common Excl. Extra. Items -65.367 -39.306 -16.62 -0.11954 -0.00145
Income Available to Common Incl. Extra. Items -65.367 -39.306 -16.62 -0.11954 -0.00145
Diluted Net Income -65.367 -39.306 -16.62 -0.11954 -0.00145
Diluted Weighted Average Shares 21.029 17.176 5.252 1.70157 6.25
Diluted EPS Excluding Extraordinary Items -3.10842 -2.28843 -3.16451 -0.07025 -0.00023
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.99101 -2.28843 -3.16451 -0.07025 -0.00023
Interest Income (Expense), Net Non-Operating 6.967 23.358 -5.906 0.05427
Selling/General/Admin. Expenses, Total 18.953 22.575 3.598
Research & Development 52.152 40.081 7.116
Other, Net 1.24 -0.008
Unusual Expense (Income) 2.469
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 11.66 15.099 15.423 16.901 19.623
Selling/General/Admin. Expenses, Total 3.787 4.512 4.05 4.525 4.722
Research & Development 7.873 10.587 11.373 11.066 13.742
Operating Income -11.66 -15.099 -15.423 -16.901 -19.623
Interest Income (Expense), Net Non-Operating 0.209 0.484 0.429 0.125 1.202
Net Income Before Taxes -11.151 -14.341 -13.643 -16.879 -18.421
Net Income After Taxes -11.151 -14.341 -13.643 -16.879 -18.421
Net Income Before Extra. Items -11.151 -14.341 -13.643 -16.879 -18.421
Net Income -11.151 -14.341 -13.643 -16.879 -18.421
Income Available to Common Excl. Extra. Items -11.151 -14.341 -13.643 -16.879 -18.421
Income Available to Common Incl. Extra. Items -11.151 -14.341 -13.643 -16.879 -18.421
Diluted Net Income -11.151 -14.341 -13.643 -16.879 -18.421
Diluted Weighted Average Shares 21.274 21.188 21.14 21.083 20.995
Diluted EPS Excluding Extraordinary Items -0.52416 -0.67685 -0.64536 -0.8006 -0.8774
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.52416 -0.67685 -0.64536 -0.73846 -0.8222
Other, Net 0.3 0.274 1.351 -0.103 0
Unusual Expense (Income) 0 0 1.31 1.159
  • Annual
  • Quarterly
2022 2021 2020 2020 2019
Total Current Assets 55.964 111.841 63.11 0.79104 0.025
Cash and Short Term Investments 52.459 111.459 61.792 0.68471 0.025
Cash 0.68471 0.025
Total Assets 59.286 117.676 63.192 66.483 0.025
Other Long Term Assets, Total 0.081 1.653 0.082 0
Total Current Liabilities 9.156 13.919 37.813 0.11626 0.00145
Payable/Accrued 4.715 0.11545 0.00145
Accrued Expenses 5.947 0.738 0
Notes Payable/Short Term Debt 0 0 0.014 0 0
Total Liabilities 11.618 17.355 37.813 3.41358 0.00145
Total Long Term Debt 0 0 0 0 0
Total Equity 47.668 100.321 25.379 63.0694 0.02355
Common Stock 0.002 0.002 0.001 58.0696 0.00014
Additional Paid-In Capital 169.03 156.311 42.043 5.12076 0.02486
Retained Earnings (Accumulated Deficit) -121.338 -55.971 -16.665 -0.12099 -0.00145
Total Liabilities & Shareholders’ Equity 59.286 117.676 63.192 66.483 0.025
Total Common Shares Outstanding 21.2429 21.0576 13.9844 8.20471 6.25
Prepaid Expenses 1.694 0.182 1.104 0.10633
Long Term Investments 65.6919
Other Current Liabilities, Total 0.144 6.447 37.308 0.00081
Other Liabilities, Total 2.462 3.436 3.29732
Cash & Equivalents 11.663 111.459 61.792
Other Current Assets, Total 0.439 0.2 0.214
Accounts Payable 3.065 2.019 0.491
Other Equity, Total -0.026 -0.021 0
Property/Plant/Equipment, Total - Net 3.241 4.182
Short Term Investments 40.796
Total Receivables, Net 1.372
Property/Plant/Equipment, Total - Gross 3.32
Accumulated Depreciation, Total -0.079
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 22.818 31.813 44.007 55.964 67.255
Cash and Short Term Investments 20.802 27.359 39.768 52.459 65.975
Cash & Equivalents 15.078 6.679 4.489 11.663 45.804
Prepaid Expenses 0.322 0.636 0.807 0.134 0.47
Other Current Assets, Total 0.641 2.434 3.432 3.371 0.81
Total Assets 26.276 35.275 47.448 59.286 72.376
Property/Plant/Equipment, Total - Net 2.584 2.838 3.087 3.241 3.479
Other Long Term Assets, Total 0.874 0.624 0.354 0.081 1.642
Total Current Liabilities 8.846 9.157 10.712 9.156 9.95
Accounts Payable 3.062 3.533 6.173 3.065 4.393
Payable/Accrued 4.526 4.288 3.355 4.445
Accrued Expenses 1.126 1.092 1.058 5.947 0.999
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.132 0.244 0.126 0.144 0.113
Total Liabilities 10.535 11.139 12.982 11.618 12.669
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.689 1.982 2.27 2.462 2.719
Total Equity 15.741 24.136 34.466 47.668 59.707
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 172.232 170.895 170.108 169.03 167.463
Retained Earnings (Accumulated Deficit) -156.545 -146.83 -135.679 -121.338 -107.695
Other Equity, Total 0.052 0.069 0.035 -0.026 -0.063
Total Liabilities & Shareholders’ Equity 26.276 35.275 47.448 59.286 72.376
Total Common Shares Outstanding 21.3806 21.3806 21.2458 21.2429 21.1898
Short Term Investments 5.724 20.68 35.279 40.796 20.171
Total Receivables, Net 1.053 1.384
  • Annual
  • Quarterly
2022 2021 2020 2020 2019
Net income/Starting Line -65.367 -39.306 -16.62 -0.11954 -0.00145
Cash From Operating Activities -59.604 -33.402 -2.279 -0.16533 0
Changes in Working Capital -1.02 5.609 -0.959 0.00848 0.00145
Cash From Financing Activities 0.28 88.453 64.071 66.4627 0.025
Financing Cash Flow Items 64.07 0.60279 0
Issuance (Retirement) of Stock, Net 0.28 88.453 0.001 65.8599 0.025
Net Change in Cash -99.831 49.772 61.792 0.65971 0.025
Non-Cash Items 6.729 0.27 15.3 -0.05427
Cash From Investing Activities -40.578 -5.258 -65.6377
Other Investing Cash Flow Items, Total -40.578 -5 -65.6377
Cash Taxes Paid 0
Cash Interest Paid 0 0.025 0.025
Issuance (Retirement) of Debt, Net 0 0
Cash From Operating Activities 0.054 0.025
Capital Expenditures 0 -0.258
Foreign Exchange Effects 0.071 -0.021
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -14.341 -65.367 -51.724 -34.845 -16.424
Cash From Operating Activities -13.092 -59.604 -45.787 -30.915 -15.028
Non-Cash Items 0.861 6.729 5.177 2.642 0.263
Cash Taxes Paid 0
Cash Interest Paid 0 0 0 0 0
Changes in Working Capital 0.375 -1.02 0.72 1.261 1.119
Cash From Investing Activities 5.885 -40.578 -20.195 0 0
Other Investing Cash Flow Items, Total 5.885 -40.578 -20.195 0 0
Net Change in Cash -7.174 -99.831 -65.696 -30.644 -15.011
Capital Expenditures 0 0 0
Cash From Financing Activities 0.003 0.28 0.242 0.242
Issuance (Retirement) of Stock, Net 0.003 0.28 0.242 0.242
Issuance (Retirement) of Debt, Net
Cash From Operating Activities 0.013 0.054 0.04 0.027 0.014
Foreign Exchange Effects 0.03 0.071 0.044 0.029 0.017
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Goldman Sachs & Company, Inc. Research Firm 9.6487 2062950 -1942 2023-06-30 MED
Sage Rhino Capital, LLC Investment Advisor 7.9671 1703413 16476 2023-09-30 LOW
Hamdy (Ahmed) Individual Investor 7.9135 1691959 59480 2023-03-28 LOW
Izumi (Raquel E.) Individual Investor 7.8947 1687937 69738 2023-03-28 LOW
Byrd (John C) Individual Investor 7.5685 1618199 0 2023-03-28 LOW
Affinity Asset Advisors LLC Hedge Fund 6.9819 1492771 0 2023-06-30 HIGH
Long Focus Capital Management LLC Hedge Fund 5.139 1098753 -316198 2023-06-30 MED
Rock Springs Capital Management LP Hedge Fund 4.1707 891719 0 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 3.0894 660522 36595 2023-06-30 LOW
Schonfeld Strategic Advisors LLC Hedge Fund 2.814 601645 -29277 2023-06-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.4334 520269 0 2023-06-30 LOW
ExodusPoint Capital Management, LP Hedge Fund 1.9947 426472 34724 2023-06-30 HIGH
Kingdon Capital Management, L.L.C. Hedge Fund 1.8007 385000 0 2023-06-30 HIGH
Rubric Capital Management LP Hedge Fund 1.6575 354377 -32342 2023-06-30 MED
Point72 Asset Management, L.P. Hedge Fund 1.6128 344828 -488 2023-06-30 HIGH
Tejara Capital Ltd. Investment Advisor 1.0914 233348 -57534 2023-06-30 HIGH
Baker Bros. Advisors LP Hedge Fund 1.0551 225579 -15800 2023-06-30 LOW
Thomas (Tom C) Individual Investor 1.0053 214939 5000 2023-08-10
Renaissance Technologies LLC Hedge Fund 0.7441 159100 -35900 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6402 136878 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vincerx Pharma, Inc. Company profile

About Vincerx Pharma Inc

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and oncology knowledge to advance new therapies for the treatment of cancer. The Company’s small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds addressing known and novel oncology targets. The Company’s bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Vincerx Pharma Inc revenues was not reported. Net loss totaled to $32.8M. Results are not comparable due to year end change.

Industry: Bio Therapeutic Drugs

260 Sheridan Avenue
Suite 400
PALO ALTO
CALIFORNIA 94306
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

US100

18,100.40 Price
-0.630% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

78.36 Price
0.000% 1D Chg, %
Long position overnight fee 0.0264%
Short position overnight fee -0.0483%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

66,898.95 Price
-0.980% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,126.30 Price
+0.580% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0107%
Overnight fee time 22:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading